Using RbM to Evaluate Site Engagement

Case Study

Clinical trial site engagement has been advocated as a critical component relating to a study’s performance and success, however, a minimum amount of data supports this connection.

In this article a reader will find quantitative and qualitative approach based on risk-based monitoring (RbM) to assess study site engagement, develop monitoring risk tool-kits and strategies for specific countries and regions. The authors answer the question: “What can study teams do to mitigate pre-inherent site engagement risks in large trials?”

Download the Case Study

Cyntegrity Clinical Site Engagement

By |2016-11-16T18:35:46+00:00March 24, 2015|Case Study|0 Comments

About the Author:

Professional in the integration of data-driven Risk-based Monitoring (RbM) process in international clinical trials of pharmacology. Speaker at regional and global conferences such as: DIA, PharmaForum, PharmaDay, DGGF, etc. 10+ years of experience in data quality projects and biostatistics for the pharmaceutical industry. Life passion: improving clinical research with RbM, driving the RbM research to new frontiers for CROs, pharma and biotech companies.

Leave A Comment

Upcoming Events

  1. DIA Europe 2019

    February 5 - February 7

Register Today!

Get Free Test Access